Abstract:Objecitve To compare the short-term efficacy and adverse reactions of oxaliplatin combined with capecitabine (XELOX) and oxaliplatin combined with tegafur-gimeracil-oteracil potassium(S-1) (SOX) in patients with advanced gastric cancer. Methods Fifty patients with advanced gastric cancer from June 2016 to June 2019 were studied retrospectively.According to different chemotherapy regimen, they were divided into oxaliplatin combined with capecitabine group (XELOX group, n=20) and oxaliplatin combined with tegio group (SOX group, n=30).The efficacy and adverse reactions were observed and compared between two groups, and the related factors of prognosis were analyzed. Results There were no significant differences in objective remission rate(35.0% vs 33.3%) and disease control rate (65.0% vs 60.0%)between XELOX group and SOX group (P>0.05).After treatment, leukocyte decline (grade Ⅱ-Ⅲ), hand and foot syndrome(gradeⅠ-Ⅱ) and diarrhea mostly occurred in XELOX group, while platelet decline (grade Ⅱ-Ⅲ) occurred mainly in SOX group.The incidence of hand-and-foot syndrome in XELOX group was significantly higher than that in SOX group(P<0.01). Conclusion Both XELOX and SOX have a certain therapeutic effect on advanced gastric cancer and similar short-term curative effect with tolerable adverse reactions and could be used as the first-line treatment of choice without significant difference in the short-term curative effect.The primary site of tumor may be related to prognosis of patients, and the prognosis of patients with peritoneal metastasis is poor.